Emergence Therapeutics AG Announces Key Hirings to Senior Management Team

Substantial experience in cancer targets, ADC technology as well as corporate finances and law

Duisburg, Germany – Marseille, France, 22 January 2020: Emergence Therapeutics announced today that is has hired Florence Lhospice as Chief Development Officer and Carsten Dehning as Chief Financial Officer and member of the Executive Board to complement its management team. Dr. Florence Lhospice joins Emergence from Innate Pharma where she has been Senior Director, head of ADC development, head of CMC and Program Manager. Carsten Dehning is the former CEO and CFO of Biovertis, CFO of Albireo Pharma and DeveloGen, and Chairman and CEO of Aspireo Pharmaceuticals.

The management team further comprises co-founder and Chief Executive Officer, Dr. Jack Elands, founder of Talix Therapeutics, CEO of BliNK Biomedical and former CEO of Amakem and Vitec; Chief Scientific Officer and co-founder, Dr. Xavier Preville, former CSO at Talix Therapeutics, director of preclinical development at Transgene and BT Pharma (Genticel).

Dr. Jack Elands, Chief Executive Officer of Emergence Therapeutics, commented: “Dr. Florence Lhospice has significant experience in the biotech industry and brings major CMC and ADC expertise to the company. As Chief Development officer Florence will be responsible for formal preclinical and CMC related development. Carsten Dehning enriches the management team with his substantial expertise in corporate management, finances and legal matters. With Florence and Carsten on board we now have a great team of biotech experts with many years of experience. And with a growing network of further experts around us we are fully equipped to deliver on our goals.”

Latest News


Emergence Therapeutics Licenses Synaffix ADC Technology Platform in $360M Deal

Synaffix to provide access to proprietary ADC technologies (GlycoConnect™, HydraSpace™ and exatecan-based SYNtecan E™ linker-payload) Emergence Therapeutics secures rights to develop multiple ADCs against undisclosed targets to strengthen its ADC pipeline Emergence Therapeutics becomes the tenth company to license the Synaffix ADC technology platform in a deal with a total potential value of up to...

View Article >

Emergence Therapeutics strengthens leadership team with the appointment of Hatem Azim as Chief Medical Officer

Duisburg, Germany, 7 June 2022. Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers with high unmet needs, today announces the appointment of Hatem Azim, MD, PhD, as Chief Medical Officer (“CMO”), as of 6 June 2022. Dr. Hatem Azim joins Emergence Therapeutics from Pierre Fabre, a...

View Article >

Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC

Series A round led by Pontifax and includes new and existing investors Lead product is a next-generation Nectin-4 ADC designed to increase efficacy and minimize toxicity Strategy is to become a dominant ADC developer   Duisburg, Germany, 7 December 2021. Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment...

View Article >